Humacyte, Inc. 8K

Humacyte, Inc. announced Q2 2026 results featuring positive Phase 3 ATEV dialysis data driving a planned sBLA, advancement of its CTEV CABG program, commercial and regulatory progress for Symvess, a $57.5 million equity raise, and a cost-reduction restructuring amid ongoing net losses.

On August 12, 2026, Humacyte, Inc. reported its second quarter 2026 financial results and corporate update, highlighting breakthrough top-line interim Phase 3 results from its V012 trial in female dialysis access patients in which its acellular tissue engineered vessel (ATEV) significantly outperformed the standard-of-care AV fistula and will support a planned supplemental Biologics License Application filing with the FDA in the second half of 2026; the company also announced FDA acceptance of an IND for its coronary tissue engineered vessel (CTEV) with a Phase 2a CABG study expected to start in Q3 2026, ongoing commercialization initiatives and modest revenue growth for Symvess, acceptance of a marketing authorization application for Symvess in Israel, new U.S. Department of Defense funding support for bioengineered blood vessel procurement, a June 2026 public equity offering raising $57.5 million of gross proceeds, and a May 2026 cost-reduction program including a workforce restructuring expected to yield approximately $14.3 million in 2026 savings, alongside continued operating losses and an improved cash position of $80.3 million as of June 30, 2026.

Filing Facts

CIK

1818382

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-094440

Alert Tier

7